Invention:
This invention is a new anti-cancer peptide for treatment of Triple-Negative Breast Cancer (TNBC). This new peptide-based therapeutic focuses on blocking of Epidermal Growth Factor Receptor (EGFR) and SNX1. In addition, this peptide blocks the secretion of harmful exosomes that further cancer cell metastasis and modulate the immune environment.
Background:
Triple-negative breast cancer (TNBC) accounts for about 10-15% of all breast cancers. TNBC tends to grow quickly, is more likely to have spread at the time it’s found and is more likely to come back after treatment than other types of breast cancer, contributing to lower survival rates than other breast cancer types. Currently, the use of Paclitaxel as a taxane approach, or a PARP inhibitor such as Olaparib is the standard method of treatment of Triple-Negative Breast Cancer. Recently, blocking peptides have been found to be effective in fighting existing tumors, but also serves to prevent exosome secretion from cancerous cells. Stopping this exosome secretion and production allows for a novel approach to tumor-regression that limits metastasis and is one of its largest sources. Additionally, exosomes are being evaluated as biomarkers for diagnostic approaches.
Applications:
- Triple Negative Breast Cancer therapeutic
Advantages:
- Potential applications in diagnostics as a biomarker
- Shown decrease in metastatic progression
- Halts production of exosomes
- Novel peptide-based therapeutic
- Effective method in fighting Triple Negative Breast Cancer
